Re: All things CoronaVirus
Posted: Wed Sep 08, 2021 12:10 pm
More of a general response because a lot of folks toss around production costs as if that’s all it costs to develop a drug. Either they don’t understand or try to make it opaque, not that I thought you were doing that but somebody spent a lot of dough coming up with these, not to mention all the failed R&D that doesn’t pay off at allwgdsr wrote: ↑Wed Sep 08, 2021 12:07 pmya, i'm not sure how those treatment courses were priced overseas. it is a 40 year old drug of course now in generic, and if you can get an rx it looks like $10-25 stateside:Farfromgeneva wrote: ↑Wed Sep 08, 2021 11:59 amNot to defend or justify but production cost of all Medication that doesn’t include R&D expenses is just not useful. I prefer the European model of capitalizing R and expensing D but in the US we put both into a capital expenditure and the intangible asset bucket to be amortized over the life the the drug.wgdsr wrote: ↑Wed Sep 08, 2021 11:41 amit is being used in africa. and in latin america. and in india. probably a good deal others. based on what, i'm not rabbit holing that.RedFromMI wrote: ↑Wed Sep 08, 2021 10:11 am Ivermectin usage for COVID-19 is not recommended by most of the medical establishment simply because there is not enough evidence that it actually works better than a placebo. There are SOME studies, AFAIK mostly flawed in some way, that show a positive effect, but others which do not.
So if the risk of using (and an antiparasitic agent definitely has risks) is greater than the benefit, why choose it?
the fcccc? doc posted several days ago listed a good many studies that aren't randomized, double blinded, mostly from latin america. a number of studies were large, with some outsized (50-75%) results.
the principle trial double blind/randomized should be robust and have results i think? in months, not years. also an arm for favipiravir. they're setting a 14 day limit from test/symptoms and a baseline for symptoms/at risk. personally if we're trying out these anti-inflammatories, anti-virals for early treatment options i wish they'd do something much closer to symptoms/test and all manner of candidates. can't have everything. many ivm treatment studies or protocols being used have more of a whole kit of prescribed treatments, though i have no idea if they're supposed to work in concert to amplify any possible gain.
any event, if there is any outsized gain for ivm or favipiravir "early", it should? show with the first larger trial.
given we've not found an effective early/anti-viral yet proven to our standards, it's like cov-2 has gotten the better of those mechanisms. slippery.
the market is hopping for ivm. supposedly ~$ 0.12 to make in india at least, and going for $500-800 in some countries (couple bucks in bangladesh). and in 2020, india production jumped 4 1/2 fold. wonder what 2021 will be.
https://www.business-standard.com/artic ... 005_1.html
https://www.medrxiv.org/content/10.1101 ... 147v1.full
https://www.webmd.com/rx/drug-prices/ivermectin